

НП АК «ПАМ»

249030, Киевское ш., д.3, г. Обнинск, Калужская обл., Россия
Для переписки: 249031, а/я 1024, г. Обнинск, Калужская обл., Россия
Тел.: (484) 399-72-58, факс: (484) 396-58-79
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

NP AC PAM

249030, Kievskoye sh., 3, Obninsk, Kaluga region, Russia
For letters: 249031, P.O.Box 1024, Obninsk, Kaluga region, Russia
Tel: (484)399-72-58, fax: (484)396-58-79
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

Dear colleagues,


We would like to devote this April Digest to our electronic Investment platform "**Intellect•Inform•Invest**" (www.pam-iii.ru).

Alliance of Competences "PAM" offers an ever-expanding pipeline of biopharmaceutical and medical projects. The Investment platform provides an opportunity to obtain full, current and reliable information about the projects.


The website offers information about secured advanced research projects. These projects have successfully passed the professional subject studies, during which preliminary safety and pharmacological efficiency evaluation of a potential drug were conducted on experimental models, while patentability and pharmaceutical market opportunities were assessed.

Each project contains information about the potential application domain, its mechanism of action, major competitive advantages, as well as relevant information about accomplished research milestones and upcoming works.

The priority research areas of projects are: oncology, neurodegenerative diseases, infectious diseases, cardiovascular system and metabolism, reproductive system. We are planning to update the pipeline at the site with the projects of the following areas: diagnostics, nutritional therapy.



Radio- and Chemo-protector, Adjuvant of Radio- and Chemotherapy
(PAM-9)



Compound with Antiviral Activity Against Influenza and Other Acute Respiratory Infection Viruses
(PAM-1)



Anticancer Compound
(PAM-14)



Compound for the Reproductive Function Recovery
(PAM-8)



Oxygen Carrier
(PAM-3)



Dementia Treatment Compound
(PAM-43)

In addition to the current information about projects you have the opportunity to get acquainted with the general rules of the Investment platform functioning and obtain full information about each project's financial situation and possible financial transactions.

A potential investor can use the feedback services and ask any questions about the project, its progress and receive a prompt response. Thus the site allows you to create an overall impression of the project.

You can find below (next page) an overview of the actively developing projects in the pipeline of Alliance of Competences "PAM", research areas and stages.

For more information about the projects and the Investing platform please visit the website www.pam-iii.ru.

For more current information about the Alliance, the key strategies and priorities, its institutions, please visit the website of the Alliance www.pam-alliance.ru.

With kind regards and best wishes,

Rakhim Roziev, MD, PhD

НПАК «ПАМ»

249030, Киевское ш., д.3, г. Обнинск, Калужская обл., Россия
Для переписки: 249031, а/я 1024, г. Обнинск, Калужская обл., Россия
Тел.: (484) 399-72-58, факс: (484) 396-58-79
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

NP AC PAM

249030, Kievskoye sh., 3, Obninsk, Kaluga region, Russia
For letters: 249031, P.O.Box 1024, Obninsk, Kaluga region, Russia
Tel: (484)399-72-58, fax: (484)396-58-79
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

Actively Developing Projects in Alliance of Competences “Park of Active Molecules” Pipeline

Infectious diseases	PAM-1	Low-toxic drug for treatment of influenza and other acute respiratory viral infections	<u>Phase I Clinical Trial</u> has ended.
	PAM-31	Compound treating infectious diseases caused by various RNA-containing viruses	Substance laboratory operating procedures are being developed
Oncology	PAM-9	Radio- and chemoprotector, adjuvant of radio- and chemotherapy	<u>Phase II Clinical Trial</u> has started (as a radioprotector)
	PAM-14	Anticancer compound	Pharmacological activity has been studied. Preclinical toxicity studies are being led.
Reproductive science	PAM-8	Compound for the Reproductive Function Recovery	Phase II Clinical Trial has started
Neuroscience	PAM-12	Compound for treatment of Alzheimer's type dementia	Pharmacological activity has been studied. Preclinical toxicity studies are being led.
	PAM-28	Compound for treatment of autism spectrum disorders	Pharmacological activity has been studied. Preclinical toxicity studies have been led.
	PAM-38	Compound for treatment of mild cognitive impairment	Preclinical functional activity has been carried out. Phase I Clinical trial is planned for autumn 2016.
	PAM-43	Compound for treatment of dementia of various etiologies	Preliminary preclinical functional studies has been carried out.
Cardiovascular system	PAM-3	Compound assuring oxygen transportation to tissues and stimulates the hemopoiesis under insufficient blood supply	Ministry of Healthcare authorization has been obtained to lead <u>Phase I Clinical Trials</u>
	PAM-4	Antiarrhythmic compound with combined effect	Pharmacological activity has been studied. Preclinical toxicity studies of the pharmaceutical substance have been led.
Mabolism	PAM-10	Compound for prevention and treatment of metabolic syndrome (diabetes, arteriosclerosis, hypertension and ischemic disease)	Pharmacological activity has been studied. Preclinical safety and pharmacokinetic studies have been led.
	PAM-41	Compound for prevention and treatment of diabetes mellitus type 2	Pharmacological activity has been studied.